Key Developments: Inovio Pharmaceuticals Inc (INO.O)

INO.O on Nasdaq

9.01USD
18 Dec 2014
Price Change (% chg)

-- (--)
Prev Close
$9.01
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,136,521
52-wk High
$15.80
52-wk Low
$7.48

Search Stocks

Latest Key Developments (Source: Significant Developments)

Inovio Pharmaceuticals Inc initiates DNA Immunotherapy Trial for Breast, Lung and Pancreatic Cancers
Thursday, 18 Dec 2014 06:00am EST 

Inovio Pharmaceuticals Inc:Says it has initiated a phase I trial of its hTERT DNA immunotherapy (INO-1400) alone or in combination with Inovio's IL-12 immune activator (INO-9012) in adults with breast, lung, or pancreatic cancer at high risk of relapse after surgery and other cancer treatments.Says study will be conducted at the University of Pennsylvania's Abramson Cancer Center, which will fund all site-specific clinical study costs.Says this study will evaluate Inovio's novel immunotherapy with the ultimate goal of reducing the risk of relapse in these patients.Says primary objective of this study is to evaluate the safety and tolerability of INO-1400 alone or in combination with INO-9012, delivered intramuscularly in subjects with high-risk breast, lung, or pancreatic cancer with no evidence of disease after surgery and adjuvant therapy.Says the secondary objectives are to evaluate cellular and humoral immune responses, measure time to disease progression, and evaluate immunotherapy-induced changes in subjects.  Full Article

Inovio Pharmaceuticals added to NASDAQ Biotechnology Index
Monday, 15 Dec 2014 08:00am EST 

Inovio Pharmaceuticals:Says it has been added to the NASDAQ Biotechnology Index (NBI).The addition to the NASDAQ Biotechnology Index will become effective upon market open on Dec. 22.  Full Article

Inovio Pharmaceuticals Inc ebola vaccine moving into human trial with GeneOne Life Science
Wednesday, 24 Sep 2014 06:00am EDT 

Inovio Pharmaceuticals Inc:Says it will advance its DNA vaccine for Ebola into a phase I clinical trial in collaboration with GeneOne Life Science Inc.Says collaboration Inovio and GeneOne will co-develop Inovio's DNA-based Ebola vaccine through a phase I clinical trial.Says companies are currently conducting pre-IND activities and plan to start the clinical study in the first half of 2015.Says upon successful completion of the phase I, the companies will jointly seek additional third party support and resources to further develop and commercialize this product.  Full Article

Inovio Pharmaceuticals Inc expands HPV Immunotherapy development to Aerodigestive Cancers
Monday, 22 Sep 2014 08:00am EDT 

Inovio Pharmaceuticals Inc:Initiates phase I clinical trial in patients with aerodigestive cancers.The trial will evaluate the safety, tolerability, and immunogenicity of INO-3106.This immunotherapy targets human papillomavirus type 6 (HPV-6), which causes most aerodigestive cancers.Aerodigestive cancers affect the lips, mouth, tongue, nose, throat, vocal cords, and parts of the esophagus and windpipe.Unmet need for patients suffering from this form of cancer is significant.This study is part of Inovio's strategy to broadly expand clinical development of its DNA-based immune therapy products to treat different HPV types and the many diseases they cause.It is a phase I, open label compassionate study enrolling patients with invasive cancer who have exhausted all other treatment options (chemotherapy, radiation and surgery).Study will test Inovio's immunotherapy, INO-3106, alone or in combination with DNA-based IL-12, Inovio's proprietary immune activator, in subjects with HPV-6 associated aerodigestive malignancies.Successful results could open a path to pursuing an FDA orphan designation (special status granted for therapies for rare diseases) for aerodigestive cancers.  Full Article

Inovio Pharmaceuticals begins trading on NASDAQ Global Select Market Exchange
Monday, 15 Sep 2014 08:59am EDT 

Inovio Pharmaceuticals Inc:Met the stringent listing criteria for the NASDAQ Global Select Market and has transferred to this U.S. stock exchange from the NYSE MKT.Company will continue to trade under its current ticker symbol, "INO.".  Full Article

Inovio Pharmaceuticals Inc initiates cervical cancer clinical trial
Monday, 23 Jun 2014 04:00am EDT 

Inovio Pharmaceuticals Inc:Initiated phase I/IIa clinical trial to evaluate safety, immunogenicity, clinical responses and disease-free survival of DNA immunotherapy product, INO-3112, in treating human papillomavirus (HPV)-associated cervical cancer.Says INO-3112 is combination of Inovio's lead active immunotherapy product, VGX-3100, and its proprietary immune activator expressing interleukin-12 (IL-12).Each INO-3112 treatment will be combination of 6 mg of VGX-3100 and 1 mg of DNA-based IL-12 delivered together intramuscularly with the CELLECTRA delivery system.Says VGX-3100 is being evaluated in a randomized phase II efficacy trial for the treatment of high grade cervical dysplasia (pre-cancer).This open-label study, called HPV-004, will evaluate INO-3112 in 20 female subjects with inoperable invasive cervical cancer.Cervical cancer study is being conducted at University of Chicago Medical Center and at the Comprehensive Cancer Center.  Full Article

Inovio Pharmaceuticals Inc initiates immune therapy trial for Head & Neck Cancer Caused by HPV
Tuesday, 10 Jun 2014 04:00am EDT 

Inovio Pharmaceuticals Inc:Says it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity and clinical responses of its immunotherapy product, INO-3112, in treating human papillomavirus (HPV)- associated head and neck cancer.Says INO-3112 is a combination of Inovio's lead active immunotherapy product, VGX-3100, and its proprietary immune activator expressing interleukin-12 (IL-12).Says VGX-3100 is currently being evaluated in a randomized phase II efficacy trial for the treatment of high grade cervical dysplasia (pre-cancer).  Full Article

Inovio Pharmaceuticals subsidiary sells animal health assets
Tuesday, 27 May 2014 04:00am EDT 

Inovio Pharmaceuticals Inc:Says VGX Animal Health, Inc to sell animal health assets to Plumbline Life Sciences, Inc. (PLS) of Korea.Assets being transferred includes exclusive license with Inovio for animal applications of its growth hormone-releasing hormone (GHRH) technology and animal DNA vaccines plus a non-exclusive license to Inovio electroporation delivery systems.VGX Animal Health to receive $2 mln in cash in multiple payments and 20pct of outstanding shares of PLS.  Full Article

Inovio Pharmaceuticals Inc closes $63.3 mln underwritten financing
Tuesday, 4 Mar 2014 09:49am EST 

Inovio Pharmaceuticals Inc:Closed its previously announced underwritten public offering of 21,810,900 shares of the Company's common stock.Including 2,844,900 shares of common stock issued pursuant to the underwriter's exercise of its overallotment option, at the public offering price of $2.90 per share.Gross proceeds of this offering were about $63.3 mln.Net proceeds to the company, after deducting the underwriter's discounts and commission and other estimated offering expenses payable by the company, were about $59.2 million.  Full Article

Inovio Pharmaceuticals Inc announces pricing of public offering of common stock
Thursday, 27 Feb 2014 09:00am EST 

Inovio Pharmaceuticals Inc:Says the pricing of an underwritten public offering of 18,966,000 shares of common stock for a public offering price of $2.90 per share.Says the gross proceeds to Inovio from this offering are expected to be about $55 mln.Says it has granted to the underwriters participating in the offering a 30-day option to purchase up to an additional 2,844,900 shares of common stock to cover over-allotments.Says the offering is expected to close on or about march 4th.Says it intends to use the net proceeds for general corporate purposes, and potential acquisitions of companies and technologies that complement its business.Piper Jaffray & Co. and Stifel, Nicolaus & Company, Incorporated are acting as joint bookrunning managers for the offering.Brean Capital, LLC and Maxim Group LLC are acting as co-managers of the offering.  Full Article

Inovio to start human trials of Ebola vaccine

- Vaccine developer Inovio Pharmaceuticals Inc said the company and its partner GeneOne Life Science Inc will start testing its experimental Ebola vaccine in humans in the first half of 2015.

Search Stocks